| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
A multinational report on SARS-CoV-2 infection outcomes in people with CF and Aspergillus infection or ABPA
|
Bradbury, Jacob D.
|
|
|
23 |
2 |
p. 354-363
|
article
|
| 2 |
Association of Pseudomonas aeruginosa incident infections with adherence to cystic fibrosis foundation care guidelines
|
Shah, Kushal S.
|
|
|
23 |
2 |
p. 300-305
|
article
|
| 3 |
Can we decondition TRIKAFTA® tablets for the younger ones?
|
Gabsi, Asma
|
|
|
23 |
2 |
p. 364-365
|
article
|
| 4 |
Characteristics associated with cystic fibrosis-related pulmonary exacerbation treatment location
|
Gold, Laura S.
|
|
|
23 |
2 |
p. 278-281
|
article
|
| 5 |
Chronic rhinosinusitis in people with CF, a rapidly changing field
|
Mainz, Jochen G.
|
|
|
23 |
2 |
p. 183-184
|
article
|
| 6 |
Chronic rhinosinusitis in the era of CFTR modulator therapy
|
Stone, Roy Gavin
|
|
|
23 |
2 |
p. 208-213
|
article
|
| 7 |
Effects of elexacaftor/tezacaftor/ivacaftor on liver fibrosis markers in adults with cystic fibrosis
|
Tewkesbury, Daniel H
|
|
|
23 |
2 |
p. 349-353
|
article
|
| 8 |
Electronic home monitoring of children with cystic fibrosis to detect and treat acute pulmonary exacerbations and its effect on 1-year FEV1
|
Yanaz, Muruvvet
|
|
|
23 |
2 |
p. 329-333
|
article
|
| 9 |
Elexacaftor/tezacaftor/ivacaftor improves chronic rhinosinusitis detected by magnetic resonance imaging in children with cystic fibrosis on long-term therapy with lumacaftor/ivacaftor
|
Wucherpfennig, Lena
|
|
|
23 |
2 |
p. 234-241
|
article
|
| 10 |
Elexacaftor/Tezacaftor/Ivacaftor therapy in cystic fibrosis children previously CFSPID: Is it over-medicalization?
|
Terlizzi, V.
|
|
|
23 |
2 |
p. 366-367
|
article
|
| 11 |
Frequent microbiological surveillance during inpatient cystic fibrosis pulmonary exacerbations has limited clinical value
|
Song, Wendy HC
|
|
|
23 |
2 |
p. 282-287
|
article
|
| 12 |
Global disparities in cystic fibrosis outcomes prior to CFTR modulators: A CF registries cohort study in South Africa and Canada
|
Zampoli, Marco
|
|
|
23 |
2 |
p. 334-340
|
article
|
| 13 |
Identification of prognostic biomarkers for antibiotic associated nephrotoxicity in cystic fibrosis
|
Hart, Andrew
|
|
|
23 |
2 |
p. 293-299
|
article
|
| 14 |
Impact of highly effective modulator therapy on chronic rhinosinusitis and health status: 2-year follow-up
|
Beswick, Daniel M.
|
|
|
23 |
2 |
p. 214-218
|
article
|
| 15 |
Influence of highly effective modulator therapy on the sputum proteome in cystic fibrosis
|
Maher, Rosemary E
|
|
|
23 |
2 |
p. 269-277
|
article
|
| 16 |
Innovation in care closer to home for people with cystic fibrosis: The importance of evaluating and collaborating
|
Daniels, Tracey E
|
|
|
23 |
2 |
p. 181-182
|
article
|
| 17 |
Letter to the editor: A contemporary assessment of CFTR modulator use and eligibility
|
Rubin, Jaime L.
|
|
|
23 |
2 |
p. 368-369
|
article
|
| 18 |
Longitudinal changes in the cystic fibrosis airway microbiota with time and treatment
|
Einarsson, Gisli G.
|
|
|
23 |
2 |
p. 252-261
|
article
|
| 19 |
Modelling the spread of cystic fibrosis in Brittany using genealogical data over five centuries
|
Pellen, Nadine
|
|
|
23 |
2 |
p. 341-348
|
article
|
| 20 |
Monitoring of ECFS quality standards for the clinical management of adults with cystic fibrosis
|
Gramegna, Andrea
|
|
|
23 |
2 |
p. 306-313
|
article
|
| 21 |
Nasal airway inflammatory responses and pathogen detection in infants with cystic fibrosis
|
Kopp, Benjamin T.
|
|
|
23 |
2 |
p. 219-225
|
article
|
| 22 |
Nasal lavage microbiome, but not nasal swab microbiome, correlates with sinonasal inflammation in children with cystic fibrosis
|
Chung, Jaehi
|
|
|
23 |
2 |
p. 226-233
|
article
|
| 23 |
News article
|
Balfour-Lynn, Ian
|
|
|
23 |
2 |
p. 179-180
|
article
|
| 24 |
Preventive service utilization among adults with cystic fibrosis covered by private insurance is comparable to the general population
|
Malhotra, Sankalp
|
|
|
23 |
2 |
p. 314-320
|
article
|
| 25 |
Quantifying variation in home spirometry in people with cystic fibrosis during baseline health, and associations with clinical outcomes
|
Thornton, Christina S.
|
|
|
23 |
2 |
p. 321-328
|
article
|
| 26 |
SPLUNC1 as a biomarker of pulmonary exacerbations in children with cystic fibrosis
|
Ben-Meir, E.
|
|
|
23 |
2 |
p. 288-292
|
article
|
| 27 |
Standards for the care of people with cystic fibrosis (CF); recognising and addressing CF health issues
|
Burgel, Pierre-Régis
|
|
|
23 |
2 |
p. 187-202
|
article
|
| 28 |
The evolving focus of cystic fibrosis microbiome research
|
Taylor, Steven L.
|
|
|
23 |
2 |
p. 185-186
|
article
|
| 29 |
The gut microbiota in adults with cystic fibrosis compared to colorectal cancer
|
Caley, L.R.
|
|
|
23 |
2 |
p. 262-268
|
article
|
| 30 |
The relationship between the intestinal microbiome and body mass index in children with cystic fibrosis
|
Bernard, Rachel
|
|
|
23 |
2 |
p. 242-251
|
article
|
| 31 |
Year in review 2023 – Back to the future
|
Cristiani, Luca
|
|
|
23 |
2 |
p. 203-207
|
article
|
Journal description